Dr. Herriot Tabuteau, M.D., is a Haitian-American physician, entrepreneur, and the self-made billionaire Founder and CEO of Axsome Therapeutics (NASDAQ: AXSM), a leading biotech company specializing in neurological and psychiatric disorders. Born in Haiti in 1968, he immigrated to the U.S. at age nine and grew up in Manhattan.

Tabuteau's background is elite: he holds a B.A. in Molecular Biology and Biochemistry from Wesleyan University and an M.D. from Yale University School of Medicine. His career began in finance, working in healthcare finance at Goldman Sachs and later as a partner at the hedge fund Healthco/S.A.C. Capital. This unique blend of science (M.D.) and Wall Street finance prepared him to lead a disruptive biotech venture.

Dr. Herriot Tabuteau founded Axsome Therapeutics in 2012 (without initial venture capital), recognizing the immense need and challenge in treating neurological and psychiatric disorders—conditions often overlooked by larger pharma companies. His strategic vision was contrarian: instead of betting on a single compound, Axsome built a portfolio of drugs while running its own clinical trials at up to 50 percent lower cost.

Axsome's breakthrough came in 2022 when the FDA approved Auvelity, the first rapid-acting oral antidepressant. The company is now on track to generate $500 million in annual sales for Auvelity, with analysts predicting the drug and others (like Sunosi) could reach blockbuster status (over $1 billion in revenue). His leadership has positioned the firm to challenge larger competitors, with shares surging and its market capitalization exceeding $6 billion. He remains the CEO, guiding Axsome toward its peak sales target of $16.5 billion.

Dr. Herriot Tabuteau's social impact is massive and humanitarian, tied to Axsome's role in discovering and delivering transformative treatments for widespread neurological and psychiatric disorders. The company's focus on rapid-acting oral antidepressants has a critical structural impact on mental health treatment globally.

His structural contribution is tied to his unique business model (low-cost trials) that makes drug development more efficient. His personal philanthropy supports various medical research and community initiatives. His career is a powerful narrative of a Haitian immigrant and physician who leveraged scientific and financial rigor to achieve immense commercial and humanitarian success.

Dr. Herriot Tabuteau maintains the professional, intellectual style of a science-executive. His attire is consistently formal and high-quality, favoring tailored suits. His aesthetic is one of stability and commanding intellectual authority, reflecting his M.D. and his mastery of both science and finance.

Residing in New York, his luxury is the immense security and autonomy derived from his multi-billion dollar fortune. His life is dedicated to biopharmaceutical innovation, strategic management, and fulfilling his mission to achieve outcomes that stand apart in medical treatment.